

Publication of knee study showing potential anti-inflammatory benefit for XPERIENCE™

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today announces the publication of a pilot study which demonstrates the utility of XPERIENCE™ in mitigating inflammation following a Total Knee Arthroplasty (TKA).

Next Science is a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health.

On 9 August 2023, Next Science announced that Dr Andrew Wickline MD had released the findings of a pilot study on VuMedi¹ which showed a potential anti-inflammatory benefit for XPERIENCE™, Next Science’s advanced surgical irrigation product.²

This is important because it suggests an expanded application for XPERIENCE™ in addition to reducing biofilm-based infection rates.

The study findings have now undergone a peer review process and been published in the *Journal of Orthopaedic Experience & Innovation*.

The article entitled “Beneficial Effects of a Novel Intraoperative Surgical Irrigant on Post-Operative Knee Swelling and Limb Function in Primary Total Knee Arthroplasty” by Andrew Wickline MD and Louis Battista can be accessed via the link below.

<https://journaloei.scholasticahq.com/article/89994>

Next Science’s CEO and Managing Director I.V. Hall said: “This pilot study by leading orthopaedic surgeon Dr. Andrew Wickline shows that the use of XPERIENCE™ has the potential to improve patient outcomes by reducing both infection and inflammation when used in Total Knee Arthroplasty procedures. The results, which first appeared in August 2023 on VuMedi, have now been through a peer review process and published in the *Journal of Orthopaedic Experience & Innovation*. This publication means the study will now receive broader recognition in the Orthopaedic community. We will continue to work closely with surgeons to conduct clinical research that further investigates the effectiveness of Next Science’s products.”

Approved and authorised for release by the Managing Director.

¹ VuMedi is a video education platform for doctors.

² Refer to ASX announcement on 9 August 2023.

NEXT SCIENCE®

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.